These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11438343)

  • 1. A case of forearm amputation after ovarian stimulation for in vitro fertilization-embryo transfer.
    Mancini A; Milardi D; Di Pietro ML; Giacchi E; Spagnolo AG; Di Donna V; De Marinis L; Jensen L
    Fertil Steril; 2001 Jul; 76(1):198-200. PubMed ID: 11438343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
    Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
    Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
    Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
    Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian hyperstimulation syndrome in a frozen-thawed embryo transfer pregnancy: a rare case report.
    Yang L; Wang R; Wang F; Wang F; Zou L
    BMC Pregnancy Childbirth; 2020 May; 20(1):313. PubMed ID: 32434545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes.
    Schirmer DA; Kulkarni AD; Zhang Y; Kawwass JF; Boulet SL; Kissin DM
    Fertil Steril; 2020 Sep; 114(3):567-578. PubMed ID: 32680613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.
    Lyons CA; Wheeler CA; Frishman GN; Hackett RJ; Seifer DB; Haning RV
    Hum Reprod; 1994 May; 9(5):792-9. PubMed ID: 7929724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total ovarian volume before human chorionic gonadotrophin administration for ovulation induction may predict the hyperstimulation syndrome.
    Oyesanya OA; Parsons JH; Collins WP; Campbell S
    Hum Reprod; 1995 Dec; 10(12):3211-12. PubMed ID: 8822446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox.
    Evbuomwan IO; Davison JM; Murdoch AP
    Fertil Steril; 2000 Jul; 74(1):67-72. PubMed ID: 10899499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case report of Ovarian hyperstimulation syndrome and corpus luteum rupture in twin pregnancies with IVF-ET.
    Luo Y; Shen H; Li H; Tan Z; Chen C; Chen W; He J
    Medicine (Baltimore); 2023 Jul; 102(27):e34238. PubMed ID: 37417637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.
    Enskog A; Henriksson M; Unander M; Nilsson L; Brännström M
    Fertil Steril; 1999 May; 71(5):808-14. PubMed ID: 10231037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.